Travere Therapeutics Stock Price

0.09 (0.69%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Travere Therapeutics Inc TVTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.09 0.69% 13.07 12:04:41
Open Price Low Price High Price Close Price Prev Close
13.185 12.75 13.22 12.98
Bid Price Ask Price Spread News
13.04 13.09 0.05 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,289 261,639 $ 12.99 $ 3,399,549 - 12.75 - 33.0899
Last Trade Time Type Quantity Stock Price Currency
12:03:56 93 $ 13.07 USD


Draw Mode:

Travere Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 790.18M 60.46M 59.98M $ 198.32M $ -166.07M -3.53 -3.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 75.17k 5.50%

more financials information »

Travere Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TVTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week13.8114.488612.7513.65479,159-0.74-5.36%
1 Month15.4415.9112.7514.79744,200-2.37-15.35%
3 Months24.6425.18512.7516.12868,198-11.57-46.96%
6 Months27.6133.089912.7521.11735,627-14.54-52.66%
1 Year25.1533.089912.7521.91646,034-12.08-48.03%
3 Years25.1533.089912.7521.91646,034-12.08-48.03%
5 Years25.1533.089912.7521.91646,034-12.08-48.03%

Travere Therapeutics Description

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapies for people living with rare diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often lead to end-stage kidney disease.

Your Recent History
Travere Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.